AC Immune SA (ACIU)
NASDAQ: ACIU · Real-Time Price · USD
2.800
-0.080 (-2.78%)
At close: Dec 5, 2025, 4:00 PM EST
2.779
-0.021 (-0.75%)
After-hours: Dec 5, 2025, 7:51 PM EST
AC Immune Employees
As of December 31, 2024, AC Immune had 172 total employees, including 133 full-time and 39 part-time employees. The number of employees increased by 11 or 6.83% compared to the previous year.
Employees
172
Change (1Y)
11
Growth (1Y)
6.83%
Revenue / Employee
$31,878
Profits / Employee
-$524,035
Market Cap
277.04M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ACIU News
- 4 weeks ago - AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 6 weeks ago - First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune's ACI-19626 in Precision Medicine - GlobeNewsWire
- 4 months ago - AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 7 months ago - AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 8 months ago - AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease - GlobeNewsWire
- 9 months ago - AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 - GlobeNewsWire
- 9 months ago - AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 1 year ago - AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients - Benzinga